Bengaluru: Novo Nordisk, Denmark headquartered healthcare company has appointed Vikrant Shrotriya as Managing Director & Corporate Vice President for the India business. Melvin Dsouza, ex-MD, helmed the company since 2006 and led operations for India, Nepal and Bhutan. It is not clear why Dsouza stepped down.
Shrotriya, who till recently held the position of Vice-President for Novo Nordisk’s GCC business and Corporate Vice President for Saudi Arabia returns to India after 13 years.
Talking about his new role, Vikrant said, “It’s an immense honour to lead the India operations of Novo Nordisk and I am very happy to be back after a gap of 13 years. India is an important market for us, and our focus is on enhancing healthcare through awareness and education. We will continue to work on improving access to quality care by working closely with the relevant stakeholders.”
Shrotriya has had an overall distinguished career spanning over 20 years in the healthcare industry, in India and internationally. A graduate of Symbiosis Institute of International Business (SIIB), Pune, Vikrant has worked in many national and international organisations in India, South East Asia and more recently in the GCC (Gulf Cooperation Council) countries. Vikrant will be based in Bengaluru.
Recently Novo Nordisk has been taking heat for the high prices of its insulin. In the USA, Novo Nordisk said on Thursday (2nd Jan) it would offer free, one-time supply of insulin to people in immediate need and at risk of rationing the medication, the rising price of which has attracted fierce criticism from lawmakers and regulators. Novo on Thursday also announced the launch of cheaper versions of its heavily prescribed insulin drug, Novolog.
